Cytori Therapeutics, Inc. today confirmed that two Japanese regenerative medicine laws, which went into effect on November 25, 2014, remove regulatory uncertainties and provide a clear path for the Company to commercialize and market Cytori Cell Therapya and its CelutionA System under the Company's existing and planned regulatory approvals. "Now, Cytori's point-of-care Celution System can be transparently integrated into clinical use by providers under our Class I device status and the streamlined approval process granted to cell therapies that pose the lowest risk.
http://ift.tt/1ysfVZN
http://ift.tt/1ysfVZN
No comments:
Post a Comment